Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
brigatinib tyrosine-protein kinase abl1 small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Mutation[MeSHID:D009154]
Growth[MeSHID:D006128]
Continuance of life[MeSHID:D013534]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Microtubules[MeSHID:D008870]
Signal Transduction[MeSHID:D015398]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]		 NA approved,investigational inhibitor
brigatinib alk tyrosine kinase receptor small molecule Successful target TTD , drugbank , DGIDB Malignant Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Mutation[MeSHID:D009154]
Growth[MeSHID:D006128]
Continuance of life[MeSHID:D013534]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Microtubules[MeSHID:D008870]
Signal Transduction[MeSHID:D015398]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]		 4.02 approved,investigational inhibitor
brigatinib epidermal growth factor receptor small molecule NA drugbank , DGIDB Malignant Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Mutation[MeSHID:D009154]
Growth[MeSHID:D006128]
Continuance of life[MeSHID:D013534]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Microtubules[MeSHID:D008870]
Signal Transduction[MeSHID:D015398]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]		 0.5 approved,investigational inhibitor
brigatinib receptor tyrosine-protein kinase erbb-2 small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Mutation[MeSHID:D009154]
Growth[MeSHID:D006128]
Continuance of life[MeSHID:D013534]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Microtubules[MeSHID:D008870]
Signal Transduction[MeSHID:D015398]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]		 NA approved,investigational inhibitor
brigatinib receptor tyrosine-protein kinase erbb-4 small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Mutation[MeSHID:D009154]
Growth[MeSHID:D006128]
Continuance of life[MeSHID:D013534]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Microtubules[MeSHID:D008870]
Signal Transduction[MeSHID:D015398]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]		 NA approved,investigational inhibitor
brigatinib receptor-type tyrosine-protein kinase flt3 small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Mutation[MeSHID:D009154]
Growth[MeSHID:D006128]
Continuance of life[MeSHID:D013534]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Microtubules[MeSHID:D008870]
Signal Transduction[MeSHID:D015398]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]		 NA approved,investigational inhibitor
brigatinib insulin-like growth factor 1 receptor small molecule NA drugbank , DGIDB Malignant Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Mutation[MeSHID:D009154]
Growth[MeSHID:D006128]
Continuance of life[MeSHID:D013534]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Microtubules[MeSHID:D008870]
Signal Transduction[MeSHID:D015398]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]		 1.01 approved,investigational inhibitor
brigatinib insulin receptor small molecule NA drugbank , DGIDB Malignant Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Mutation[MeSHID:D009154]
Growth[MeSHID:D006128]
Continuance of life[MeSHID:D013534]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Microtubules[MeSHID:D008870]
Signal Transduction[MeSHID:D015398]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]		 0.21 approved,investigational binding,inhibitor
brigatinib hepatocyte growth factor receptor small molecule NA drugbank Malignant Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Mutation[MeSHID:D009154]
Growth[MeSHID:D006128]
Continuance of life[MeSHID:D013534]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Microtubules[MeSHID:D008870]
Signal Transduction[MeSHID:D015398]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Ki-1+ Anaplastic Large Cell Lymphoma[MeSHID:D017728]		 NA approved,investigational inhibitor
click here to return to the previous page